Welcome to our dedicated page for HeartSciences SEC filings (Ticker: HSCS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
HeartSciences’ AI-powered ECG technology turns a routine heart trace into an early warning system, but its SEC disclosures can be just as data-rich. Whether you need the HeartSciences quarterly earnings report 10-Q filing to track R&D burn or want to confirm how many patents moved to issuance this quarter, Stock Titan surfaces the answers immediately.
Our platform ingests every HSCS submission the moment it hits EDGAR and delivers understanding HeartSciences SEC documents with AI. Skip the jargon: AI summaries flag trial milestones in an 8-K, highlight revenue guidance buried in a 10-Q, and decode equity grants inside the HeartSciences proxy statement executive compensation. You can even monitor HeartSciences Form 4 insider transactions real-time to see exactly when executives buy or sell shares.
Use cases include:
- Reviewing a HeartSciences annual report 10-K simplified for patent pipeline details and regulatory risk factors.
- Setting alerts for HeartSciences 8-K material events explained – from FDA feedback to new distribution agreements.
- Tracking HeartSciences executive stock transactions Form 4 before pivotal clinical announcements.
From HeartSciences earnings report filing analysis to granular HeartSciences insider trading Form 4 transactions, every data point arrives with clear commentary, trend charts, and exportable tables. Complex medical-device disclosures are now approachable: real-time updates, AI interpretation, and complete coverage of 10-K, 10-Q, 8-K, S-1, and more—all in one place.
HeartSciences Inc. filed a Form S-8 to register 209,857 shares of common stock for issuance under its 2023 Equity Incentive Plan, reflecting the plan’s Evergreen Provision increase as of May 1, 2025. The filing also includes a reoffer prospectus of up to 252,561 shares that may be resold from time to time by certain affiliates, inclusive of the newly reserved shares.
The company will not receive proceeds from affiliate resales; it would receive cash only if outstanding employee stock options are exercised. Separately, on July 9, 2025, the company increased the plan’s reserve to 1,000,000 shares plus Evergreen, a change that has not yet been approved by shareholders.
As context, shares of common stock outstanding were 3,071,135 prior to the offering and 3,323,696 after, as shown in the prospectus table; this is a baseline share count, not the amount being registered for issuance.
FAQ
What is the current stock price of HeartSciences (HSCS)?
What is the market cap of HeartSciences (HSCS)?
